Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

68° Partly Cloudy

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2026

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.40 +0.26 (+1.03%)

Delayed Quote Updated: 1:24 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run ↗

April 08, 2022

FDA action just sent this red-hot biotech stock to a high, continuing its strong run.

Via Investor's Business Daily

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval ↗

April 08, 2022

Via Benzinga

Amphastar Receives FDA Approval for Ganirelix Acetate Injection

April 08, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating ↗

April 07, 2022

On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.

Via Investor's Business Daily

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗

April 07, 2022

On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.

Via Investor's Business Daily

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

April 06, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

April 04, 2022

Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

7 “A”-Rated Stocks to Ground Your Portfolio ↗

March 17, 2022

It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.

Via InvestorPlace

Amphastar Pharmaceuticals: Q4 Earnings Insights ↗

March 10, 2022

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021

March 10, 2022

Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Earnings Preview For Amphastar Pharmaceuticals ↗

March 09, 2022

Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022

March 03, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021,...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

February 14, 2022

Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

7 Safe Stocks to Rely On When the Market Swerves ↗

February 09, 2022

When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential.

Via InvestorPlace

Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗

February 07, 2022

The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.

Via Investor's Business Daily

Top Russell 2000 Stocks: Trading Opportunities For Next Week ↗

February 06, 2022

A security pattern traces the distinct movements of security prices that, once recognized, helps traders to make informed trading decisions. Let's look at some Russell 2000 stock opportunities by...

Via Talk Markets

64 Biggest Movers From Yesterday ↗

February 01, 2022

Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 31, 2022

Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock...

Via Benzinga

32 Stocks Moving In Monday's Mid-Day Session ↗

January 31, 2022

Gainers FGI Industries Ltd. (NASDAQ: FGI) shares jumped 42.4% to $5.37 after surging 19% on Friday. The company, last week, priced its IPO at $6 per share. Knightscope, Inc. (...

Via Benzinga

Maravai Lifesciences Stock Closes In Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 03, 2022

One key metric to look for in a stock is 80-plus RS Rating. Maravai Lifesciences stock just hit that mark, with a jump from 71 to 81 Monday.

Via Investor's Business Daily

Amphastar Receives FDA Tentative Approval for Vasopressin

December 29, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗

January 07, 2022

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:

Via Benzinga

Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 22, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Topics Regulatory Compliance

Ligand Pharmaceuticals Sees RS Rating Rise To 92 ↗

November 11, 2021

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

November 11, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Topics Regulatory Compliance

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: editor@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

Sections

Services

Follow Us